130 related articles for article (PubMed ID: 28636094)
21. Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.
Melo JV; Goldman JM
Leukemia; 1992 Aug; 6(8):786-90. PubMed ID: 1353550
[TBL] [Abstract][Full Text] [Related]
22. Persistent clonal chromosomal abnormalities in a chronic myeloid leukemia patient.
Muraoka M; Washio K; Kanamitu K; Kanazawa Y; Ishida T; Miyamura T; Chayama K; Nishiuchi R; Oda M; Shimada A
Pediatr Int; 2016 Jan; 58(1):53-6. PubMed ID: 26542480
[TBL] [Abstract][Full Text] [Related]
23. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
[TBL] [Abstract][Full Text] [Related]
24. [Chronic myeloid leukemia--update].
Tobler A; Solenthaler M
Ther Umsch; 2004 Feb; 61(2):143-50. PubMed ID: 15018397
[TBL] [Abstract][Full Text] [Related]
25. [Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy].
Yuan T; Wang XY; Lai YY; Qin YZ; Shi HX; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):547-553. PubMed ID: 32397016
[No Abstract] [Full Text] [Related]
26. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
Lai Y; Qin Y; Huang X; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
[TBL] [Abstract][Full Text] [Related]
27. [Application of fluorescence in situ hybridization technique in diagnosis of variant Ph chromosome translocation and Ph-negative chronic myelocytic leukemia].
Jing Y; Jiang F; Lin S; Wang FT; Fang MY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Oct; 27(5):563-6. PubMed ID: 20931538
[TBL] [Abstract][Full Text] [Related]
28. Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays.
Bennour A; Saad A; Sennana H
Crit Rev Oncol Hematol; 2016 Jan; 97():263-74. PubMed ID: 26412717
[TBL] [Abstract][Full Text] [Related]
29. Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy.
Wang H; Jin J; Wang Y; Huang X; Huang J
Ann Hematol; 2013 Dec; 92(12):1625-32. PubMed ID: 23793947
[TBL] [Abstract][Full Text] [Related]
30. Serial cytogenetic studies in allografted patients with chronic myeloid leukemia.
Bilhou-Nabera C; Bernard P; Marit G; Viard F; Gharbi MJ; Wen Z; Lacombe F; Broustet A; Reiffers J
Bone Marrow Transplant; 1992 Apr; 9(4):263-8. PubMed ID: 1600414
[TBL] [Abstract][Full Text] [Related]
31. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.
Johansson B; Fioretos T; Mitelman F
Acta Haematol; 2002; 107(2):76-94. PubMed ID: 11919388
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Groves MJ; Sales M; Baker L; Griffiths M; Pratt N; Tauro S
Cancer Genet; 2011 Jan; 204(1):39-44. PubMed ID: 21356190
[TBL] [Abstract][Full Text] [Related]
33. Case Report of acute myeloid leukemia with "WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19" developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy.
Zhu H; Yang B; Liu J; Wu W; Ling Y
Medicine (Baltimore); 2020 Jan; 99(3):e18888. PubMed ID: 32011516
[TBL] [Abstract][Full Text] [Related]
34. Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia.
Konstantinidou P; Szydlo RM; Chase A; Goldman JM
Bone Marrow Transplant; 2000 Jan; 25(2):143-6. PubMed ID: 10673671
[TBL] [Abstract][Full Text] [Related]
35. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
36. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
37. Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
Kelani R; Monem F
Int J Lab Hematol; 2015 Oct; 37(5):723-8. PubMed ID: 26059167
[TBL] [Abstract][Full Text] [Related]
38. The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for chronic myelogenous leukemia.
Wakim JJ; Tirado CA; Dowell J; Chen W
Cancer Genet; 2012 Mar; 205(3):124-7. PubMed ID: 22469511
[TBL] [Abstract][Full Text] [Related]
39. Cytogenetic peculiarities in chronic myelogenous leukemia.
Hild F; Fonatsch C
Cancer Genet Cytogenet; 1990 Jul; 47(2):197-217. PubMed ID: 2357695
[TBL] [Abstract][Full Text] [Related]
40. Absence in Ph-negative, M-BCR rearrangement-positive chronic myelogenous leukemia of linkage between 5' ABL and 3' M-BCR sequences in Philadelphia translocation.
Nishigaki H; Misawa S; Inazawa J; Abe T
Leukemia; 1992 May; 6(5):385-92. PubMed ID: 1593904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
